-
Product Insights
FCA US – Windsor Plant Expansion – Ontario
Equip yourself with the essential tools needed to make informed and profitable decisions with our FCA US - Windsor Plant Expansion - Ontario report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
FCA Automobiles – Hyderabad Global Digital Hub Development – Telangana
Equip yourself with the essential tools needed to make informed and profitable decisions with our FCA Automobiles - Hyderabad Global Digital Hub Development - Telangana report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Company Profile
![]()
FCA US LLC – Company Profile
FCA US LLC (FCA US), formerly known as Chrysler Group LLC, designs, engineers, manufactures, distributes and sells vehicles. The company offers products such as passenger cars, minivans, sport utility vehicles, pickup trucks and commercial vehicles under brands such as Dodge, Jeep, Fiat, Mopar, Lancia, Chrysler, Ram, Abarth and Alfa Romeo. In addition, the company provides retail and dealer financing, leasing, rental and aftermarket services. It primarily operates in North America and sells its products in the US, Canada, Mexico and...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Pyoderma Gangrenosum
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Pyoderma Gangrenosum Drug Details: Canakinumab (Ilaris / Lasprona / Vyncro) is a fully...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Sickle Cell Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Sickle Cell Disease Drug Details: Canakinumab (Ilaris / Lasprona / Vyncro) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Anemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Anemia Drug Details: Canakinumab (Ilaris / Lasprona / Vyncro) is a fully human...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Myelodysplastic Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Myelodysplastic Syndrome Drug Details: Canakinumab (Ilaris / Lasprona / Vyncro) is a fully...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Metastatic Melanoma Drug Details: Canakinumab (Ilaris / Lasprona / Vyncro) is a fully...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Pancreatic Ductal Adenocarcinoma Drug Details: Canakinumab (Ilaris / Lasprona / Vyncro) is a...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Triple-Negative Breast Cancer (TNBC) Drug Details: Canakinumab (Ilaris / Lasprona / Vyncro) is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Pulmonary Sarcoidosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Pulmonary Sarcoidosis Drug Details: Canakinumab (Ilaris / Lasprona / Vyncro) is a fully...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anakinra in Intracerebral Hemorrhage
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Intracerebral Hemorrhage Drug Details: Anakinra (Kineret) is an immunosuppressant produced in Escherichia coli...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anakinra in Sepsis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Sepsis Drug Details: Anakinra (Kineret) is an immunosuppressant produced in Escherichia coli cells...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anakinra in Community Acquired Pneumonia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Community Acquired Pneumonia Drug Details: Anakinra (Kineret) is an immunosuppressant produced in Escherichia...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anakinra in Myocarditis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Myocarditis Drug Details: Anakinra (Kineret) is an immunosuppressant produced in Escherichia coli cells...
-
Product Insights
NewUnited Kingdom (UK) Travel Insurance Market Dynamics, Trends and Opportunities
The UK travel insurance market experienced growth of 73.1% in 2022, reaching a value of GBP630.4 million. This was mainly due to a rise in premiums, with the average premium for single-trip and multi-trip policies rising by 10.9% and 101.7% respectively. This came despite the number of policies written falling by 4.2% in 2022, as consumers reduced discretionary spending amid the cost-of-living crisis. The cost-of-living crisis has also led to claims inflation within the industry, which in turn has prompted...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anakinra in Hospital Acquired Pneumonia (HAP)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Hospital Acquired Pneumonia (HAP) Drug Details: Anakinra (Kineret) is an immunosuppressant produced in...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anakinra in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anakinra in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) Drug Details: Anakinra (Kineret) is an...
-
Sector Analysis
Automotive ADAS and Autonomous Vehicles Market Trends and Analysis by Technology, Companies and Forecast to 2028
Automotive ADAS And Autonomous Vehicles Market Report Overview The autonomous and ADAS-enabled vehicle market is estimated at 498.4 mn units in 2023. The market is expected to record a CAGR of more than 6% during 2023-2028. The development of autonomous and ADAS-enabled vehicles is largely reliant on sensors and the accompanying development of predictive software. The main hardware used in ADAS systems, and to be used in autonomous vehicles, consists of radar, Lidar, and cameras. ADAS and Autonomous Vehicles Market...
-
Analyst Opinions
United Kingdom (UK) Insurance Aggregators Market Trends and Analysis by Line of Business, Competitor Profiles and Marketing Strategies
United Kingdom (UK) Insurance Aggregators Market Report Overview Aggregators, also referred to as PCWs (price comparison website) represent one of the leading channels in the UK for researching and purchasing insurance. PCWs are the third most frequently used distribution channel in the UK following the direct and broker channels for personal insurance products. Aggregators are emerging as a research tool benefitting consumers looking for the best value for their money. The core benefit of PCWs is the speed and ease...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.